Kyntra Bio CFO granted 26,000 stock options

Q: Who is the reporting person in the Kyntra Bio (KYNB) Form 4 filing?

The reporting person is David DeLucia, the Chief Financial Officer of Kyntra Bio, Inc. He is identified as an officer, not a director or 10% owner, and this filing reflects an option grant directly held in his name as beneficial owner.

Q: How many Kyntra Bio (KYNB) options were granted to the CFO and at what price?

The CFO received a grant of 26,000 stock options relating to Kyntra Bio common stock. Each option carries an exercise price of $8.50 per share. These options are recorded as derivative securities beneficially owned following the reported transaction.

Q: What is the vesting schedule of the Kyntra Bio (KYNB) stock options granted to the CFO?

The stock option vests in equal amounts quarterly over four years, measured from 02/03/2026. This means portions of the 26,000-share option become exercisable every quarter until the full grant is vested by the end of the four-year period.

Q: When do the granted Kyntra Bio (KYNB) stock options expire?

The granted stock options have an expiration date of 02/02/2036. After this date, any unexercised portion of the 26,000-share option will lapse. Until expiration, vested portions can be exercised at the fixed $8.50 per share exercise price.

Q: How many Kyntra Bio (KYNB) derivative securities does the CFO own after this transaction?

After this transaction, the CFO beneficially owns 26,000 derivative securities, all from this stock option grant. The ownership is reported as direct, meaning the options are held in his own name rather than through an intermediary entity or indirect structure.

Kyntra Bio, Inc. reported an option grant to its Chief Financial Officer, David DeLucia.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kyntra Bio, Inc. reported an option grant to its Chief Financial Officer, David DeLucia. On 02/03/2026, he was awarded a stock option for 26,000 shares of common stock at an exercise price of $8.50 per share.

The option vests in equal amounts quarterly over four years starting on 02/03/2026. Following this grant, DeLucia beneficially owns 26,000 derivative securities directly through this option award.

Insider Trade Summary

Grant/Award: 26,000 shares

Grant/Award 1 txn

Insider DeLucia David

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	26,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 26,000 contracts (Direct)

Footnotes (1)

F1. The option vests in equal amount quarterly over 4 years measured from 2/3/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kyntra Bio (KYNB) disclose in this Form 4?

Kyntra Bio disclosed a stock option grant to its Chief Financial Officer, David DeLucia. He received options for 26,000 shares of common stock at an exercise price of $8.50 per share, recorded as an acquisition of derivative securities on 02/03/2026.

Who is the reporting person in the Kyntra Bio (KYNB) Form 4 filing?

The reporting person is David DeLucia, the Chief Financial Officer of Kyntra Bio, Inc. He is identified as an officer, not a director or 10% owner, and this filing reflects an option grant directly held in his name as beneficial owner.

How many Kyntra Bio (KYNB) options were granted to the CFO and at what price?

The CFO received a grant of 26,000 stock options relating to Kyntra Bio common stock. Each option carries an exercise price of $8.50 per share. These options are recorded as derivative securities beneficially owned following the reported transaction.

What is the vesting schedule of the Kyntra Bio (KYNB) stock options granted to the CFO?

The stock option vests in equal amounts quarterly over four years, measured from 02/03/2026. This means portions of the 26,000-share option become exercisable every quarter until the full grant is vested by the end of the four-year period.

When do the granted Kyntra Bio (KYNB) stock options expire?

The granted stock options have an expiration date of 02/02/2036. After this date, any unexercised portion of the 26,000-share option will lapse. Until expiration, vested portions can be exercised at the fixed $8.50 per share exercise price.

How many Kyntra Bio (KYNB) derivative securities does the CFO own after this transaction?

After this transaction, the CFO beneficially owns 26,000 derivative securities, all from this stock option grant. The ownership is reported as direct, meaning the options are held in his own name rather than through an intermediary entity or indirect structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/05/2026 - 09:06 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeLucia David

(Last)

(First)

(Middle)

C/O KYNTRA BIO INC.

350 BAY STREET, SUITE 100 # 6009

(Street)

SAN FRANCISCO

94133

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.5	02/03/2026		A		26,000		⁽¹⁾	02/02/2036	Common Stock	26,000	$0	26,000	D

Explanation of Responses:

1. The option vests in equal amount quarterly over 4 years measured from 2/3/2026.

	/s/ John Alden, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR